🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are thrilled to share our recent publication in European Urology Oncology demonstrating for the first time CHAI based predictive biomarker to guide use of intravesical BCG vs alternatives (chemotherapy). In an era of BCG shortage and new alternatives to BCG incoming, precision medicine

This is a cool graph

📺 Dr. Sia Daneshmand, M.D. moderates a new roundtable series featuring guest panelists Mark Tyson, Aaron Berger, MD, of Associated Urological Specialists, and Vignesh Packiam, MD discussing the evolving treatment and diagnostic landscape of #NMIBC: buff.ly/UbJobkE ⭐ In part 1, the panelists

💡The best systematic reviews bring together a host of treatments in one paper for an easy reference 👏Saum Ghodoussipour et al. do that for #NMIBC strategies European Urology 🔗shorturl.at/iKtml Roger Li Sarah P. Psutka MD MS Mark Tyson Bladder Cancer Advocacy Network Gianluca Giannarini

Focus. Precision. Skill. Alain Kaldany, MD Rachel Passarelli Two of our very best Rutgers RWJ Urology and future GURS superstars 🌟New York Section AUA SWIU #UroSoMe RWJBarnabas Robert Wood Johnson University Hospital

100% agree - NMIBC extremely heterogeneous and extent of CIS is one of the many factors

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

Phase 3 oncology RCTs often report positive results based on alternative end points, but actual improvements in overall survival or quality of life are rare, highlighting need to prioritize these outcomes in future research & regulatory processes. #ASCO25 ja.ma/3FCoVHI

Exercise has as much definitive benefit of many of our more “medical” therapies!

Very cool data. I hear so many questions about what patients can change to reduce their risk of bladder cancer. Is this the direct impact of animal proteins or microbiome? bjui-journals.onlinelibrary.wiley.com/doi/10.1002/bc…

Early phase IIT to suggest favorable outcome with Taxol/CPI in UC. Kudos to Rohan Garje, MD for putting this IIT as 3rd year fellow UI Holden Comprehensive Cancer Center now GU leader Miami Cancer Institute Research and to #Aditya current fellow University of Iowa Health Care for closing the loop with pub sciencedirect.com/science/articl…

First paper out from my lab! 🎉 Thrilled to share our work on molecular profiling of Ta low-grade bladder cancer, published in European Urology Oncology: 🔗sciencedirect.com/science/articl… Many thanks to Joep J. de Jong, Peter Black, and Lars Dyrskjøt! #bladdercancer #genomics #NMIBC #uroonc

The first patient has been dosed in a phase 2 trial investigating MVR-T3011, an oncolytic immunotherapy for patients with BCG-unresponsive high-risk NMIBC. Vignesh Packiam, MD #blcsm urologytimes.com/view/phase-2-t…

Our take on radiation for NMIBC in European Urology Saum Ghodoussipour Melinda Fu authors.elsevier.com/a/1lFCk14kpm0h…

🚨BREAKING: The #FDA has approved mitomycin intravesical solution (Zusduri, formorly UGN-102) for the treatment of patients with recurrent low-grade intermediate-risk NMIBC. urologytimes.com/view/fda-appro…

A comprehensive review about the role of tumor microenvironment on the immunotherapy response! OncoAlert Nature Cancer #Cancer #Oncology #MedTwitter nature.com/articles/s4301…

What a treat to host the inimitable Sia Daneshmand, M.D. USC Urology as our center's 2025 Rutgers RWJ Urology Rutgers Cancer Institute #Urology Visiting Prof! His journey & impact on our field incredibly inspiring #UroSoMe New York Section AUA Society of Urologic Oncology Testicular Cancer Bladder Cancer Advocacy Network IBCG Amer. Urol. Assn.

Really like this idea! There is morbidity to every procedure esp with prolonged bladder sparing in this era. I think many are already selectively doing repeat TURBT & considering skipping if a trustworthy resection with blue light was performed and path relatively favorable

A true honor to serve as VP Rutgers RWJ Urology. Incredible division led by empowering Thomas Jang with star faculty Saum Ghodoussipour Vignesh Packiam, MD David Golombos RoboUroMD Chrystal Chang, MD Danielle Leitner. Excited for future of stunning new Rutgers Cancer Institute Center. Thx to all residents for

Great overview Joshua Meeks ! Its valuable that prospective Gem/Doce is in some BCG-unresponsive trial pipelines Retro data consistently shows 1year CR is ~60% pubmed.ncbi.nlm.nih.gov/39694798/ pubmed.ncbi.nlm.nih.gov/31821066/ And I am reassured that so far Max Kates prospective Tx naive data is